Evidence map›Paper›PMID 40813103›Full record

ArticleFamily medicine and community health2025

Process for mainstreaming genetic cascade testing into primary and tertiary health systems in familial hypercholesterolaemia (FH), an autosomal dominant, fully penetrant disorder.

Karen L Birkenhead, David Sullivan, Madeline Calder, Catherine Spinks, Gabrielle Fleming, Claire Trumble, Cameron Hemmert, Ronald Trent, Shubha Srinivasan, Kerrie Martin and 3 more

Abstract read
In one paragraph

Article in Family medicine and community health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Karen L BirkenheadSchool of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia karen.birkenhead@sydney.edu.au.ORCID 0000-0002-8311-7794
David SullivanDepartment of Chemical Pathology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Madeline CalderInstitute of Precision Medicine and Bioinformatics, Sydney Local Health District, Sydney, New South Wales, Australia.
Catherine SpinksInstitute of Precision Medicine and Bioinformatics, Sydney Local Health District, Sydney, New South Wales, Australia.
Gabrielle FlemingInstitute of Precision Medicine and Bioinformatics, Sydney Local Health District, Sydney, New South Wales, Australia.
Claire TrumbleInstitute of Precision Medicine and Bioinformatics, Sydney Local Health District, Sydney, New South Wales, Australia.
Cameron HemmertSchool of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Ronald TrentInstitute of Precision Medicine and Bioinformatics, Sydney Local Health District, Sydney, New South Wales, Australia.
Shubha SrinivasanInstitute of Endocrinology and Diabetes, The Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Kerrie MartinClinical Genetics Network and Ophthalmology Network, Agency for Clinical Innovation, Sydney, New South Wales, Australia.
Bridie CarrCardiac Network, Agency for Clinical Innovation, Sydney, New South Wales, Australia.
Charlotte M HespeSchool of Medicine, University of Notre Dame Australia, Sydney, New South Wales, Australia.ORCID 0000-0002-4582-7728
Mitchell SarkiesSchool of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAdvances in clinical genomics have raised the importance of integrating genomic medicine across healthcare systems, including primary care. Primary care presents an ideal environment to offer equitable and efficient access to genetic services. Familial hypercholesterolaemia (FH) is a preventable and treatable cause of premature heart disease and represents a health condition that can be successfully diagnosed and managed in primary care. This study describes a process for tailoring a primary-tertiary shared care model for FH to optimise health professional and patient engagement.

methodsData were collected through semistructured interviews (n=10) with stakeholders in New South Wales, Australia. Interviews gathered feedback on how to tailor a shared care model for FH between tertiary and primary care services. Reflexive thematic analysis was used to analyse interview transcripts.

resultsAnalysis generated three main themes: (1) current process for genetic testing and management, (2) challenges with genetic testing for FH in primary care and (3) components needed to enable a tertiary-initiated shared care model. Participants considered the model of care acceptable and could be successfully implemented, provided key supports were in place to assist general practitioners. Based on these results, a process model for integrating genetic testing for other conditions into primary care settings was developed, using FH as an exemplar.

conclusionThe process model for tailoring of a primary-tertiary model of care for FH can be applied across a range of primary care services and treatable genetic conditions.

Indexed as

Genetic TestingHyperlipoproteinemia Type IIPrimary Health CareTertiary Health CareFemaleHumansInterviews as TopicMaleNew South WalesQualitative ResearchCardiovascular DiseasesGeneral PracticeGenetics, MedicalHealth Services ResearchPhysicians, Primary Care

Identifiers

PMID40813103
PMCPMC12352198

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.